Search results
What causes multiple sclerosis—and why are women more at risk?
National Geographic· 3 days agoMS affects the central nervous system, the brain and spinal cord. The immune system attacks sheaths...
Céline Dion began noticing Stiff Person Syndrome symptoms 17 years ago. What to know about the rare...
Yahoo Canada Style· 6 days agoHow is Stiff Person Syndrome treated? Currently, there is no cure for Stiff Person Syndrome. ...
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D...
Morningstar· 7 days agoAlthough estimates between studies differ, it’s commonly accepted that about 800,000-900,000 individuals in the United States suffer from MS, out of a global population of 2-3 million total ...
Céline Dion’s Doctor Makes Plea for More Stiff-Person Syndrome Research (Exclusive)
People via Yahoo News· 2 days ago“The awareness that we see with Céline bringing this to the general population… people are going to...
Multiple sclerosis disability scale: Purpose and limitations
Medical News Today· 5 days agoMultiple sclerosis (MS) disability scales are tools that can help doctors monitor the severity and...
Mesenchymal stem cell-neural progenitors beneficial for multiple sclerosis, study shows
Medical Xpress· 4 days agoSelect patients with progressive multiple sclerosis (MS) may benefit from mesenchymal stem...
Siemens Healthineers nets European approval for blood test to predict MS relapse risks
FierceBiotech· 12 hours agoSiemens Healthineers received European approval for a blood test designed to help predict the risk...
Shift Needed in Research, Treatment, for Aging MS Population
Medscape· 4 days agoFor the first time, the majority of patients with multiple sclerosis (MS) in the United States are,...
A cure for multiple sclerosis? Scientists say within our lifetime
UC Newsroom· 4 days agoPeople diagnosed today can live a long life free of disability, as UCSF research ushers in a golden...
Rituximab Tied to Increased Infection Risk in RRMS
Medscape· 5 days agoThe B-cell–depleting treatment rituximab was associated with a twofold increased risk for infection in RRMS, regardless of treatment duration or whether the patient had received other DMTs first.